Florian Muller, Ph.D.
Cancer Systems Imaging
Areas of Research
- Targeted Therapy Research
The Muller lab’s near-term career goal is to develop a small-molecule Enolase inhibitor for in vivo proof-of-principal, and ultimately, as a clinical candidate for the treatment of cancers which harbor deletions of ENO1. The secondary goal is to demonstrate the universality and expand the utility of this therapeutic strategy to other passenger deleted genes. Their tertiary goals are to use genomic deletions in cancer to gain insight into the basic biochemistry and metabolism of human cancer, as well as to utilize this knowledge for imaging purposes.
Muller’s team proposed a novel strategy for molecular targeted therapy in cancer, exploiting vulnerabilities exposed by passenger deleted genes, termed “collateral lethality”. His group presented proof-of-principal data for one example of this strategy, where glioma cells with passenger deletion of the glycolytic enzyme, ENO1 are selectively sensitive to inhibition to its redundant homologue, ENO2.
With an innate curiosity and strong satisfaction from basic discovery, their outlook is strongly translational, with success being measured by whether or not a compound is brought to the clinic.
Co-Investigator, 3 months, CPRIT – Collateral Genomic Deletions As Targetable Vulnerabilities in Cancer, RP140612, Cancer Prevention & Research Institute of Texas (CPRIT), PI - DePinho, 3/1/2015-2/28/2018
Co-Principal Investigator, 1.8 months, Nerstian Probes as Vectors for Imaging and Therapeutic Modalities in Glioblastoma, NIH/NCI, PI - Lang, Fueyo, 9/1/2015-8/31/2016
Co-Principal Investigator, 2.4 months, In Vivo Molecular Breast Imaging with TC 99M Sestamibi for the Prediction of Multidrug Resistance in Triple Negative Breast Cancers, CABI/GE IN-KIND Research Grant Multi-Investigator Imaging (M12) Research Award, PI - Rauch, 9/1/2015-8/31/2018
Principal Investigator, 2.4 months, Passenger Deletion of ENO1 as a Targetable Vulnerability in Cancer, 365082, American Cancer Society (ACS), 1/1/2016-12/31/2019
Co-Principal Investigator, 3 months, Development of an Enolase inhibitor for 1p36 homozygously deleted GBM, NIH/NCI, PI - Lang, Fueyo, 9/1/2014-8/31/2016
Postdoctoral Fellow, IRS in PI3K signaling and Glioblastoma multiforme tumor progression, T32-CA009361, NIH/NCI, PI - Charles Stilles, 1/1/2008-6/1/2008
Principal Investigator, 100%, IRS in PI3K signaling and Glioblastoma multiforme tumor progression, 115992-PF-08-261-01-TBE, American Cancer Society (ACS), 7/1/2008-6/30/2011
Principal Investigator, Reversion of Aging-related brain atrophy by telomerase re-activation, AFAR/Ellison Foundation Postdoctoral Fellowship, Ellison Medical Foundation, 7/1/2011-12/7/2011
The University of Texas MD Anderson Cancer Center
Cancer Systems Imaging
1881 East Road
Unit Number: 1907
Room Number: 3SCR4.3620
Houston, TX 77054-1901